UNSPSC 51343004: Stavudine or stavidine

This classification denotes a reverse transcriptase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BO9LE4QFZF. European Medicines Agency schedules Stavudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10642MIG. Stavudine generally arises in the molecular formula C10H12N2O4. The term STAVUDINE is an International Non-Proprietary Name or INN. STAVUDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Stavudine or stavidine bears US NLM identifiers UMLS ID C0164662 and NCI Concept Code C1428. SMILES: CC1=CN(C(=O)NC1=O)C2C=CC(O2)CO.

UNSPSC 51343004 Stavudine or stavidine is a Commodity code that shows minimal recent activity aligned with its nominal pharmaceutical scope. State and local solicitations tagged under this code are predominantly focused on naloxone procurement, medical and first aid supplies for emergency response, and broader pharmaceutical purchasing programs — none of which center on stavudine or stavidine antiretroviral therapy. The code sees solicitation activity from county health departments, state pharmaceutical benefit administrators, municipal fire departments, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. When state and local buyers do pursue pharmaceutical contracts under this taxonomy, they typically seek to fill acute operational needs (emergency medical supplies, naloxone for overdose response) or establish standing supplier relationships for broad generic and OTC product classes through cooperative purchasing mechanisms.

Recent opportunities show scattered geographic activity. Seminole County, Florida (IFB 60459723LAS, due July 26, 2023) solicited naloxone and drug deactivation systems through competitive sealed bidding; the City of Tampa (IFB 26P00145, due March 13, 2026) pursued medical and first aid supplies for its Fire Department Rescue Division as a sheltered-market contract with a $700,000 estimated value reserved for certified Small Local Business Enterprises; and the Minnesota Multistate Cooperative Purchasing Alliance (RFP S1070000015802, due March 26, 2026) established multi-state pharmaceutical contracts for generic and OTC products distributed through three authorized wholesalers, effective July 1, 2026. The Texas Health and Human Services Commission issued an RFI (HHS0017013, April 3, 2026) to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The code shows no recent solicitations specifically for stavudine or stavidine, suggesting either minimal state and local procurement demand for this antiretroviral or persistent code-classification misalignment in the broader pharmaceutical taxonomy.